Information about Pralatrexate
liver injury. Pralatrexate has been associated with a modest rate of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent
Liver safety of Pralatrexate
Mechanism of action of Pralatrexate
Pralatrexate (pral" a trex' ate) is a folate analogue which acts as an antagonist to the enzymes involved in folate dependent synthetic pathways such as thymidine synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. Inhibition of these enzymes leads to decrease in intracellular concentrations of thymidine and purine which blocks RNA and DNA synthesis and leads to apoptotic cell death in rapidly dividing cells. In vitro and in vivo studies have shown that pralatrexate has activity against peripheral T cell lymphomas, and it was approved for this use in the United States in 2009.
Clinical use of Pralatrexate
Current indications are limited to patients with refractory or relapsed peripheral T cell lymphoma.
Dosage and administration for Pralatrexate
Pralatrexate is available in single use vials of 20 or 40 mg as a solution for injection under the brand name Folotyn. The recommended dose is 30 mg/m2 given intravenously once weekly for 6 weeks in 7 week cycles.
Side effects of Pralatrexate
- Pralatrexate shares common side effects with other folate antagonists such as nausea, vomiting, diarrhea, alopecia, bone marrow suppression, peripheral neuropathy and rash.
- Uncommon, but potentially serious adverse events include febrile neutropenia, infections, dehydration, renal failure, arrhythmias and peripheral neuropathy.